News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Avigen, Inc.'s Spasticity Drug Fails in Trial, Shares Tank
October 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oct 21 (Reuters) - Biopharmaceutical company Avigen Inc said its experimental treatment for spasticity associated with multiple sclerosis (MS), AV650, failed to meet the main goal of a mid-stage trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
·
1 min read
·
Heather McKenzie
Rare diseases
Harmony Freezes Cannabidiol Gel After Phase III Miss in Fragile X Syndrome
November 5, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
November 4, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold
November 3, 2025
·
1 min read
·
Annalee Armstrong
